A share price of Rhythm Pharmaceuticals Inc [RYTM] is currently trading at $99.14, up 2.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RYTM shares have gain 0.61% over the last week, with a monthly amount drifted -2.04%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $97. Previously, Leerink Partners started tracking the stock with Outperform rating on July 07, 2025, and set its price target to $88. On April 07, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $63 on the stock. Jefferies initiated its recommendation with a Buy and recommended $80 as its price target on January 02, 2025. Oppenheimer started tracking with a Outperform rating for this stock on December 20, 2024, and assigned it a price target of $76. In a note dated October 21, 2024, Guggenheim initiated a Buy rating and provided a target price of $70 on this stock.
Rhythm Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $45.90 and $106.52. Currently, Wall Street analysts expect the stock to reach $114.5 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $99.14 at the most recent close of the market. An investor can expect a potential return of 15.49% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Trailing Twelve Months sales for Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] were 156.29M which represents 66.80% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.14%, Pretax Profit Margin comes in at -1.17%, and Net Profit Margin reading is -1.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.19 and Total Capital is -0.73. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 96.63 points at the first support level, and at 94.11 for the second support level. However, for the 1st resistance point, the stock is sitting at 100.63, and for the 2nd resistance point, it is at 102.11.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] is 2.79. In addition, the Quick Ratio stands at 2.64 and the Cash Ratio stands at 1.05. Considering the valuation of this stock, the price to sales ratio is 42.13.
Transactions by insiders
Recent insider trading involved Shulman Joseph, Chief Technical Officer, that happened on Sep 02 ’25 when 16781.0 shares were sold. Officer, JOSEPH SHULMAN completed a deal on Sep 02 ’25 to buy 16781.0 shares. Meanwhile, Chief Technical Officer Shulman Joseph sold 4188.0 shares on Aug 21 ’25.
